TY - JOUR AB - Colon cancer is a prevalent malignancy affecting the gastrointestinal tract. Oridonin (ORI) is a promising chemotherapeutic drug used in the treatment of colon cancer. In this study, we examined the anticancer activity of ORI against colon cancer and elucidated the underlying molecular mechanisms. Cell counting kit-8, flow cytometric and western blot analyses were conducted to analyze the growth inhibitory effects of ORI on SW620 cells; we employed BMP7 and p53 recombinant adenovirus to detect the influence of ORI on the p38 MAPK signal pathway; PT-qPCR, cell immunofluorescence staining and western blot analysis were used to detect the expression of BMP7, p38 and p-p38, p53 and p-p53. A xenograft tumor model and histological evaluation were introduced to detect the effects of ORI and BMP7 in SW620 cells in vivo. ORI inhibited the proliferation of SW620 cells and induced apoptosis. ORI also increased the total and phosphorylated levels of p53. The overexpression of p53 was found to enhance the anti-proliferative effects of ORI on the SW620 cells, while the inhibition of p53 partially reversed these effects. ORI increased the expression of bone morphogenetic protein 7 (BMP7) in the SW620 cells. The overexpression of BMP7 also enhanced the antiproliferative effects of ORI on the SW620 cells and reduced the growth rate of tumors in mice. BMP7-induced immunosuppression markedly decreased the anti-proliferative effects of ORI. ORI was not found to exert any substantial effect on the phosphorylation levels of Smad1/5/8, although it increased the level of p-p38 significantly. The inhibition of p38 significantly attenuated the ORI-induced increase in the levels of p-p53. The overexpression of BMP7 enhanced the promoting effects of ORI on the p-p53 and p-p38 levels, while BMP7-induced immunosuppression reduced the effects of ORI on p-p38 and p-p53. On the whole, the findings of this study suggest that ORI may be a promising agent for use in the treatment of colon cancer, and the anticancer effects of ORI may be partially mediated through the BMP7/p38 MAPK/p53 signaling pathway. AD - Department of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China AU - Liu,Rong-Xing AU - Ma,Yan AU - Hu,Xue-Lian AU - Ren,Wen-Yan AU - Liao,Yun-Peng AU - Wang,Han AU - Zhu,Jia-Hui AU - Wu,Ke AU - He,Bai-Cheng AU - Sun,Wen-Juan DA - 2018/11/01 DO - 10.3892/ijo.2018.4527 EP - 2101 IS - 5 JO - Int J Oncol KW - oridonin colon cancer bone morphogenetic protein 7 p38 mitogen-activated protein kinase p53 PY - 2018 SN - 1019-6439 1791-2423 SP - 2091 ST - Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling T2 - International Journal of Oncology TI - Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling UR - https://doi.org/10.3892/ijo.2018.4527 VL - 53 ER -